$VKTX is up 42% after VK2735 maintained up to 97% of prior weight loss on every-other-week dosing and ~90% on monthly dosing. That dosing flexibility is a real differentiator as VK2735 moves through Phase 3 with patients still losing weight at week 33 and no plateau observed. https://t.co/aejm5aWaS8
View on X ↗